KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Amortizatization of Intangibles (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Amortizatization of Intangibles for 3 consecutive years, with -$1.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Amortizatization of Intangibles rose 56.52% year-over-year to -$1.4 million, compared with a TTM value of -$9.7 million through Mar 2025, up 19.77%, and an annual FY2025 reading of -$4.3 million, up 62.25% over the prior year.
  • Amortizatization of Intangibles was -$1.4 million for Q1 2025 at Biocryst Pharmaceuticals, up from -$2.8 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at -$1.4 million in Q1 2025 and bottomed at -$3.5 million in Q2 2024.
  • Average Amortizatization of Intangibles over 3 years is -$2.6 million, with a median of -$2.8 million recorded in 2024.
  • The sharpest move saw Amortizatization of Intangibles tumbled 129.68% in 2024, then soared 56.52% in 2025.
  • Year by year, Amortizatization of Intangibles stood at -$3.4 million in 2023, then increased by 19.98% to -$2.8 million in 2024, then skyrocketed by 49.89% to -$1.4 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for BCRX at -$1.4 million in Q1 2025, -$2.8 million in Q4 2024, and -$2.0 million in Q3 2024.